Despite the huge amount of oncologic research involved in liquid biopsy, the US FDA approved only in 2016 the first liquid biopsy test for analysis of EGFR mutations in Non-Small Cell Lung Carcinoma (NSCLC) patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.